

Chemotherapy Protocols

HEAD AND NECK CANCER

Protocol	Hospital using the Protocol
Cetuximab and Radiotherapy	RSCH
Cetuximab, Cisplatin and 5-Fluorouracil	RSCH
Cisplatin and 5-Fluorouracil	RSCH
Cisplatin and Capecitabine	RSCH
Cisplatin weekly & RT	RSCH
Docetaxel	RSCH
Lenvatinib (comp use)	RSCH
Nivolumab	RSCH
Sorafenib for thyroid (stored in hepato-biliary section)	RSCH
TPF	RSCH
Vandetanib for thyroid	RSCH
Weekly Carboplatin & Radiotherapy (post TPF only)	RSCH

RSCH = Royal Surrey County Hospital

NB. The following reference sources were used routinely and are not individually referenced on each protocol:

Summary of Product Characteristics

Dose Adjustments for Cytotoxics in Renal and Hepatic Impairment, 2009 update, produced by UCLH NHS Foundation Trust

Please note: "Main Toxicities" includes only predictable and/or important side effects. For more information on side effects not mentioned, please seek further literature.

Reason for Update: Nivolumab and Lenvatinib added	Prepared by: S Taylor
Version: 12	
Supersedes: Version 11	Date: December 2017